The activation of different pathways (e.g., MET and HER2 amplification) can be the cause of resistance to TKIs, as it has already been demonstrated in patients with EGFR-mutated NSCLC progressing on osimertinib [93]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.